Wave reports WVE-006 achieves protective AAT levels in Phase 1b/2a AATD trial

Filed May 18, 2026 · Period ending May 18, 2026 · ~1 min read

Key Changes

• high

  WVE-006 generated 64% wild-type M-AAT and reduced harmful Z-AAT by 71% in 200mg biweekly cohort; 400mg monthly dosing showed similar efficacy with 13.6 µM total AAT, matching protective MZ phenotype

  Item 7.01 — Regulation FD Disclosure verify on EDGAR →
• high

  Therapy restored dynamic AAT response during acute infections, with 58-60% AAT increases during mild respiratory illness; strong correlation (r=0.73) between CRP and AAT elevation confirms physiological response

  Item 7.01 — Regulation FD Disclosure verify on EDGAR →
• high

  Editing effects sustained at least three months post-dose; no serious adverse events or liver toxicity observed, supporting convenient monthly subcutaneous dosing versus current weekly IV standard of care

  Item 7.01 — Regulation FD Disclosure verify on EDGAR →